These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 36693762)

  • 41. Recent Developments in Oligonucleotide Based Therapeutics. Preface.
    Juliano RL; Ming X
    Adv Drug Deliv Rev; 2015 Jun; 87():1-2. PubMed ID: 26175452
    [No Abstract]   [Full Text] [Related]  

  • 42. Evolution of complexity in non-viral oligonucleotide delivery systems: from gymnotic delivery through bioconjugates to biomimetic nanoparticles.
    Bakowski K; Vogel S
    RNA Biol; 2022 Jan; 19(1):1256-1275. PubMed ID: 36411594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Retention behavior of short double-stranded oligonucleotide and its potential impurities by anion-exchange chromatography under non-denaturing conditions.
    Togawa H; Okubo T; Nonaka Y; Yamaguchi T; Obika S
    J Chromatogr A; 2023 Feb; 1691():463808. PubMed ID: 36706652
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oligonucleotide therapeutics.
    Cohen JS
    Trends Biotechnol; 1992 Mar; 10(3):87-91. PubMed ID: 1371926
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular dynamics simulation and binding energy calculation for estimation of oligonucleotide duplex thermostability in RNA-based therapeutics.
    Shen L; Johnson TL; Clugston S; Huang H; Butenhof KJ; Stanton RV
    J Chem Inf Model; 2011 Aug; 51(8):1957-65. PubMed ID: 21702481
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes of the European Federation of Pharmaceutical Industries and Associations Oligonucleotide Working Group Survey on Nonclinical Practices and Regulatory Expectations for Therapeutic Oligonucleotide Safety Assessment.
    Tessier Y; Achanzar W; Mihalcik L; Amuzie C; Andersson P; Parry JD; Moggs J; Whiteley LO
    Nucleic Acid Ther; 2021 Feb; 31(1):7-20. PubMed ID: 33054599
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Building oligonucleotide therapeutics using non-natural chemistries.
    Wilson C; Keefe AD
    Curr Opin Chem Biol; 2006 Dec; 10(6):607-14. PubMed ID: 17049298
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design of 2'-
    Koizumi M; Hirota Y; Nakayama M; Tamura M; Obuchi W; Kurimoto A; Tsuchida H; Maeda H
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):292-309. PubMed ID: 31509065
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Introduction and History of the Chemistry of Nucleic Acids Therapeutics.
    Gait MJ; Agrawal S
    Methods Mol Biol; 2022; 2434():3-31. PubMed ID: 35213007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs.
    Gagnon KT; Corey DR
    Nucleic Acid Ther; 2019 Jun; 29(3):116-122. PubMed ID: 30907681
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Triazolothiadiazoles and triazolothiadiazines--biologically attractive scaffolds.
    Khan I; Ibrar A; Abbas N
    Eur J Med Chem; 2013 May; 63():854-68. PubMed ID: 23603045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and properties of oligodiaminogalactoses that bind to A-type oligonucleotide duplexes.
    Shiraishi T; Sato K; Hara RI; Wada T
    Org Biomol Chem; 2022 Nov; 20(42):8243-8258. PubMed ID: 36222332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Engineered microRNA therapeutics.
    Gibson NW
    J R Coll Physicians Edinb; 2014; 44(3):196-200. PubMed ID: 25318394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Introducing the Korean Oligonucleotide Therapeutics Society.
    Lee SW
    Nucleic Acid Ther; 2011 Jun; 21(3):123. PubMed ID: 21749288
    [No Abstract]   [Full Text] [Related]  

  • 55. New Momentum for the Field of Oligonucleotide Therapeutics.
    Aartsma-Rus A
    Mol Ther; 2016 Feb; 24(2):193-194. PubMed ID: 26906610
    [No Abstract]   [Full Text] [Related]  

  • 56. Journeying through the Field of Medicinal Chemistry: Perspectives from Graduate Researchers.
    Koerperich ZM; Kennelly SA; McDermott CM; Bentz NM; Buchholz CR; Fuller JL; Kilic O; Ge P
    J Med Chem; 2020 Mar; 63(5):1882-1891. PubMed ID: 31913619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic potential and mechanism of action of oligonucleotides and ribozymes.
    Lavrovsky Y; Chen S; Roy AK
    Biochem Mol Med; 1997 Oct; 62(1):11-22. PubMed ID: 9367793
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Mechanisms of action and patentability of therapeutic oligonucleotides].
    Crouvezier N; Marie AC; Moumné L
    Med Sci (Paris); 2023 Feb; 39(2):111-118. PubMed ID: 36799745
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Oligonucleotide therapeutics].
    Matsuda Y; Nakamura Y
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():393-7. PubMed ID: 23513872
    [No Abstract]   [Full Text] [Related]  

  • 60. Oligonucleotide analogues: an overview.
    Matteucci M
    Ciba Found Symp; 1997; 209():5-14; discussion 14-8. PubMed ID: 9383565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.